Oncology
Oncology
Cancer claims over ten million lives every year and the number continues to rise. Every patient faces a life-altering journey which exerts a physical, emotional and financial strain on themselves, their families, and even the health systems. Biocon aims to transform cancer by delivering extraordinary and affordable targeted therapies that prolong and improve patients’ lives worldwide.
While our world-class cancer-care therapies, both biosimilars and novel biologics, have seen tremendous progress in the diagnosis and treatment of cancers over the last few decades, there is still a huge unmet need of a complete cure.
Novel Biologics
NIMOTUZUMAB
Nimotuzumab is India’s first indigenously produced novel biologic for head and neck cancer, launched in India as BIOMAb EGFR® in 2006.
BIOMAb EGFR® is one of the most preferred targeted therapies in the treatment of head and neck cancers, for its excellent safety and efficacy profile.
Biosimilars
TRASTUZUMAB
Trastuzumab obtained approval as the world’s first biosimilar Trastuzumab for patients of HER2-positive metastatic breast cancer. It was launched in India as CANMAb™ in 2014.
Ogivri, co-developed with Mylan, is the first biosimilar Trastuzumab approved by the U.S. Food and Drug Administration (FDA). It has been commercialised in the U.S., EU, Canada, Australia and selected MoW markets.
